[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-diseasecad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-diseasecad":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,74,98,122,156,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100622653","study-of-lesion-specific-invasive-haemodynamic-angina-thresholds-100622653",false,"NCT07386418","Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds","ORBITA-SOLAR","Inclusion Criteria:\n\n1. Eligibility for PCI due to angina or angina-equivalent symptoms on exertion\n2. 2 severe epicardial stenoses in a major coronary artery, defined as:\n\n   1. ≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA)\n   2. Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA\n3. Evidence of ischaemia on an invasive or non-invasive test, including:\n\n   1. Physiological test during invasive coronary angiography (ICA)\n   2. Dobutamine stress echocardiography (DSE)\n   3. Stress perfusion cardiac magnetic resonance (CMR)\n   4. Myocardial perfusion scintigraphy (MPS)\n   5. Fractional flow reserve computed-tomography (FFR-CT)\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Acute coronary syndrome within 3 months\n3. Previous coronary artery bypass graft\n4. Significant left main stem disease\n5. Single lesion amenable to PCI\n6. Chronic total occlusion of the target artery\n7. Moderate to severe valve disease\n8. LVEF ≤40%, contraindication to PCI or drug-eluting stents\n9. PCI performed with drug-eluting balloons without stenting\n10. Contraindication to antiplatelet therapy\n11. Contraindication to adenosine\n12. Physical inability to exercise with an ergometer\n13. Femoral artery access\n14. Pregnancy\n15. Inability to consent","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time, at the location of each stenosis.",[26,27,28],"Angina (Stable)","Coronary Artery Disease(CAD)","Ischaemic Heart Disease (IHD)",[30,31,32,33,34],"Angina","Coronary physiology","Coronary haemodynamics","Placebo-control","Symptoms","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":39},"2026-02-10",{"date":43,"type":20},"2028-12",{"name":45,"class":46},"Imperial College London","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100580876","serial-coronary-cta-based-plaque-progression-detection-for-management-of-coronary-heart-disease-100580876","NCT06843005","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial","SUCCESS","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);\n3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.\n\nExclusion Criteria:\n\n1. Patients who have experienced ACS or PCI\u002FCABG;\n2. Patients who have experienced adverse cardiovascular and cerebrovascular events;\n3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;\n4. Patients with severe hepatic and renal dysfunction;\n5. Patients with contraindications to CCTA examinations;\n6. Patients with poor initial CCTA image quality or data loss.","80 Years",{"count":57,"type":20},3100,[23],"The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.",[61,62,27,63],"Major Adverse Cardiovascular Events (MACE)","Prevention","CT Angiography","2026-03-19",{"date":66,"type":39},"2026-03-24",{"date":68,"type":39},"2025-02-28",{"date":70,"type":20},"2028-12-30",{"name":72,"class":46},"Zhang longjiang,MD",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100626707","phase-3-comparison-of-diagnostic-accuracy-between-xtr004-pet-mpi-and-the-composite-index-of-quantitative-coronary-angiography-qca-and-fractional-flow-reserve-ffr-100626707","NCT07439133","Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)","Evaluation of the Efficacy and Safety of XTR004 Injection in Detecting Blood Flow Restrictive Stenosis in Patients With Suspected or Known Stable Coronary Artery Disease: A Multicenter, Open-Label, Phase III Clinical Trial","Inclusion Criteria:\n\n* Participants aged 18 to 80 years, male or female.\n* Suspected or confirmed patients with stable coronary heart disease. Those suspected of having stable coronary heart disease must meet at least one of the following risk factors: hypertension, hyperlipidemia, diabetes, obesity (BMI ≥28), a history of alcohol abuse, a smoking history, a family history of coronary heart disease, postmenopausal status, or age 60 years or older.\n* Participants can communicate well with investigators, understand and comply with clinical trial requirements, voluntarily participate in the study, and sign an informed consent form.\n\nExclusion Criteria:\n\n* Participants with severe cardiovascular diseases, including but not limited to unstable angina (Canadian Cardiac Society (CCS) Grade III\u002FIV angina pectoris), uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and\u002For diastolic ≥110 mmHg despite long-term regular antihypertensive medication), hypotension (resting systolic blood pressure \\\u003C90 mmHg), acute myocardial infarction, second or third-degree atrioventricular block, sinoatrial node disease, NYHA Class III\u002FIV heart failure, dilated or hypertrophic cardiomyopathy, pericarditis, valvular heart disease, aortic dissection, uncontrolled severe arrhythmias, congenital heart disease, those who have undergone coronary artery bypass grafting or interventional procedures within three months, and those determined unsuitable for participation in this study by investigators;\n* Participants with severe acute or chronic pulmonary diseases (including but not limited to COPD, asthma, bronchiectasis, emphysema, pulmonary fibrosis, pulmonary embolism, pneumonia, etc.) who are determined unsuitable for participation by the investigator;\n* Participants with severe or unstable central nervous system disorders (including but not limited to unstable cerebrovascular diseases, active epilepsy, CNS infections, CNS diseases accompanied by mental disorders or motor impairments) who are determined unsuitable for participation by the investigator;\n* Participants with severe bleeding disorders or coagulation dysfunction (including but not limited to purpura, hemophilia, vitamin K deficiency, etc.) who are determined unsuitable for participation by the investigator;\n* Participants with severe liver dysfunction (including but not limited to viral hepatitis, autoimmune hepatitis, cirrhosis, liver cancer, etc.) who are determined unsuitable for participation by the investigator;\n* Participants with severe kidney impairment (including but not limited to glomerulonephritis, renal insufficiency, nephrotic syndrome, membranous nephropathy, hydronephrosis, renal cystopathy, etc.) who are determined unsuitable for participation by the investigator;\n* Participants with fever or active infectious diseases who are determined unsuitable for participation by the investigator;\n* Participants with known alcohol allergy who are determined unsuitable for participation by the investigator;\n* participants with known adenosine allergy who are determined unsuitable for participation by the investigator;\n* Participants with known iodine contrast agent allergy who are determined unsuitable for participation by the investigator;\n* Within the past 10 years, significant occupational exposure to ionizing radiation (e.g., exceeding 50 mSv\u002Fyear) or exposure to radioactive substances or ionizing radiation for therapeutic\u002Fresearch purposes;\n* Male or women of childbearing age not using effective contraception during study participation and within 6 months post-study (effective contraception refers to sterilization, intrauterine device, condoms, abstinence, or surgical blockage of vas deferens\u002Ffallopian tubes);\n* Female participants in pregnancy or lactation\n* Individuals with claustrophobia, bipolar disorder, mental disorders, or poor compliance;\n* Participation in other investigational drug trials within 30 days prior to enrollment or planned during study;\n* Any other circumstances determined unsuitable by investigators.",{"count":82,"type":20},395,[84],"PHASE3","The primary objective of this study is to evaluate the effectiveness of visual reading in XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards in patients with suspected or known coronary artery disease.",[27],"2026-02-27",{"date":89,"type":39},"2026-03-03",{"date":91,"type":39},"2025-11-14",{"date":93,"type":20},"2027-10",{"name":95,"class":96},"Sinotau Pharmaceutical Group","INDUSTRY",5,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100616524","effect-of-femoral-region-ice-bag-application-on-patients-clinical-outcomes-post-percutaneous-coronary-intervention-100616524","NCT07306728","Effect of Femoral Region Ice Bag Application on Patients' Clinical Outcomes Post-Percutaneous Coronary Intervention","Effect of Femoral Region Ice Bag Application on Patients' Clinical Outcomes","Inclusion Criteria:\n\n\\- 1. Adult patients (aged 18 years and above) who have undergone elective PCI via femoral artery access.\n\n2\\. Patients who are conscious, oriented, and able to report pain level. 3. Hemodynamically stable post-procedure.\n\nExclusion Criteria:\n\n* 1\\. Patients with active infections 2. Patient with double femoral sheath region. 3. Patients with bleeding scar tissue from burns, wounds or hematoma in the femoral artery area before sheath removal.\n\n  4\\. Patients with known peripheral vascular disease affecting the femoral artery.\n\n  5\\. Allergy or contraindication to cold application. 6. Active bleeding at the access site. 7. Patients receiving anti-coagulation therapy beyond the standard post-PCI protocol.",{"count":19,"type":20},[23],"Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, necessitating advancements in diagnostic techniques (Parulkar et al., 2025). According to the British Heart Foundation, over 250 million individuals worldwide are living with CAD, making it the most commonly diagnosed heart condition globally. In 2021, CAD was responsible for approximately 9 million deaths, accounting for about one in every seven deaths globally",[27,109],"Percutaneous Coronary Intervention",[111],"Ice Bag Application, Clinical Outcomes, Percutaneous Coronary Intervention","NOT_YET_RECRUITING","2025-12-14",{"date":115,"type":39},"2025-12-29",{"date":117,"type":20},"2025-12-20",{"date":119,"type":20},"2026-07-30",{"name":121,"class":46},"Mansoura University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":142,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":73},"100605541","postural-mobilization-compared-to-noradrenaline-only-in-off-pump-cabg-surgery-100605541","NCT07163858","Postural Mobilization Compared to Noradrenaline Only in Off-Pump CABG Surgery","Comparison of Hemodynamic Management by Postural Mobilization Versus Chemical Vasoconstriction Using Noradrenaline Exclusively in Off-pump Coronary Artery Bypass Graft Surgery: A Prospective, Randomized, Comparative, Single-center Study.","OPTICAB","Inclusion Criteria:\n\n* Adult patient\n* patient requiring isolated coronary bypass surgery\n* Elective procedure or medical emergency\n* First cardiac surgery\n* Patient with an EF ≥30%\n* Mandatory affiliation to a social security system\n* Signed informed consent form\n* Suspension of renin-angiotensin system inhibitors and angiontensn-neprilysin receptor blockers and sartans the day before surgical procedure\n\nExclusion Criteria:\n\n* Contraindication to an inotropic substance (only NA will be used)\n* Contraindication to passive leg raising\n* Patient in a life-threatening emergency\n* History of cardiac surgery\n* Bilateral iliac or common femoral artery occlusion\n* EF \\\u003C 30%\n* Pregnancy and breastfeeding\n* Renal failure (GFR \\\u003C 40 ml\u002Fmin\u002F1.73 m²)\n* Patient with bilateral thigh amputation\n* Class III obesity BMI \\> 40 kg\u002Fm²",{"count":131,"type":20},50,[23],"This interventional prospective randomized study is designed to compare hemodynamic management using postural mobilization (+\u002F- noradrenaline) versus noradrenaline only in patients undergoing open-heart coronary artery bypass graft (CABG) surgery.",[135,27,136,137,138,139,140,141],"Coronary Artery Disease With Need for Bypass Surgery","Coronary Artery Bypass","Off Pump Coronary Artery Bypass Graft","Off Pump Coronary Artery Bypass Surgery","Hemodynamic Management","Hemodynamic Optimization","Noradrenaline",[143,144,145,146],"open-heart coronary bypass","passive leg raising","hemodynamic management","off-pump CABG surgery","2025-11-25",{"date":149,"type":39},"2025-12-03",{"date":151,"type":39},"2025-10-06",{"date":153,"type":20},"2027-08",{"name":155,"class":46},"Infirmerie Protestante de Lyon",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":4},"100605459","the-safety-and-efficacy-of-new-generation-brs-vs-dcb-for-de-novo-large-coronary-artery-lesions-a-prospective-rct-100605459","NCT07162792","The Safety and Efficacy of New-Generation BRS vs. DCB for De Novo Large Coronary Artery Lesions: A Prospective RCT","The Safety and Efficacy of New-Generation Bioabsorbable Scaffolds Versus Drug-Coated Balloons in the Treatment of De Novo Lesions in Large Coronary Arteries: A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n* \\- Radiography inclusion criteria\n\n  1. angiographically confirmed de novo coronary artery lesion;\n  2. target lesion stenosis must be ≥70% or ≥50% with clear evidence of myocardial ischaemia (visual assessment);\n  3. target lesion vessel diameter is between 2.75mm and 4.0mm, target lesion length must be ≤25mm (visual assessment);\n  4. either one or two target lesions to be treated; if two target lesions, they must be located in different target vessels;\n  5. successful target lesion preparation: residual stenosis ≤30%, no flow-restricting entrapment, and TIMI grade 3 flow; General inclusion criteria\n\n  \u003C!-- -->\n\n  1. subjects at the age between ≥18 and ≤80 years old;\n  2. patients with symptoms or evidence of myocardial ischaemia;\n  3. subjects are willing to participate in the study, sign informed consent form, and accept clinical follow-up after operation.\n\nExclusion Criteria:\n\n* 1\\. in-stent lesions; 2. For the left main disease, chronic total occlusive lesions; 3. bifurcation lesion (reference vessel diameter of side branch vessels \\> 2.0 mm); 4. Severely calcified lesions and tortuous lesions; lesions that have failed pretreatment; lesions unsuitable for balloon delivery and dilatation; 5. Previous use of any brand of drug-coated balloon in the target vessel. General inclusion criteria\n\n  1. Any patient with myocardial infarction within one month;\n  2. Patients with severe congestive heart failure (NYHA Level III severe heart failure) or severe valvular heart disease; or left ventricular ejection fraction of less than 40%;\n  3. Patients with stroke, peptic ulcer or gastrointestinal bleeding within the past 6 months; or patients with bleeding tendency or coagulation disorders;\n  4. Patients with severe liver failure (ALT and AST are larger than 3 times of the upper limit of normal value), who are judged to be not applicable to angiography by investigators;\n  5. Patients with severe renal failure(eGFR\\\u003C30ml\u002Fminute) or such medical history, failure to comply with angiography conditions;\n  6. Subjects who are intolerance or allergic to heparin, contrast agent, polyethylene oxide and polylactic acid - glycolic acid polymer;\n  7. Patients who plans to accept selective operation within 1 year;\n  8. Patients who are participating in the clinical trial of other drug or device without reaching the time limit of primary endpoint;\n  9. Subjects who are considered to be not applicable to be enrolled by investigators due to other reasons.",{"count":164,"type":20},150,[23],"This study plans to enroll 150 patients who are candidates for \"intervention without implantation\" therapy and they will be randomly assigned in a 1:1 ratio to either the new-generation Firesorb scaffold group (BRS group, N=75) or the drug-coated balloon group (DCB group, N=75). All enrolled patients will undergo angiographic follow-up at 1 year post-procedure, and serial follow-up (via telephone or outpatient visit) will be performed at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years post-procedure. The primary study endpoint was percentage diameter stenosis at 1 year post-procedure.",[27,168],"de Novo Coronary Lesions",[170,171,172],"drug-coated balloon","percutaneous coronary intervention","bioresorbable scaffold","2025-09-01",{"date":175,"type":39},"2025-09-09",{"date":177,"type":20},"2025-10-23",{"date":70,"type":20},{"name":180,"class":46},"Xuzhou Third People's Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":73},"100601213","assessment-of-coronary-artery-disease-before-transcatheter-aortic-valve-replacement-a-randomized-multicenter-non-inferiority-trial-100601213","NCT07107568","Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial","TAVR-CT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Severe aortic valve stenosis and indication for intervention according to current European Society of Cardiology (ESC) guidelines\n* TAVR candidate\n* Written informed consent\n\nExclusion Criteria:\n\n* Cardiogenic shock at presentation (e.g., emergency indication for TAVR)\n* Severe renal impairment with an estimated glomerular filtration rate of \\\u003C30 mL\u002Fmin\u002F1.73 m²\n* Life expectancy \\\u003C1 year due to other severe non-cardiac disease (e.g., malignancy)\n* Pregnancy",{"count":189,"type":20},700,[23],"The goal of this clinical trial is to determine whether a non-invasive coronary assessment strategy using photon-counting detector computed tomography (PCD-CT) is non-inferior to invasive coronary angiography (ICA) for evaluating coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.",[193,27,194],"Aortic Valve Stenosis and Insufficiency","Transcatheter Aortic Valve Replacement (TAVR)",[186,196,197,198,199,200,201],"PCD-CT","Severe Aortic Stenosis","Transcatheter Aortic Valve Replacement","TAVR","Photon-Counting Detector CT","Randomized Controlled Trial","2025-08-18",{"date":204,"type":39},"2025-08-22",{"date":206,"type":39},"2025-08-14",{"date":208,"type":20},"2029-12-31",{"name":210,"class":46},"Medical University Innsbruck"]